Rotigotine



Rotigotine
Systematic (IUPAC) name
6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol
Identifiers
CAS number 92206-54-7
ATC code N04BC09
PubChem 57537
Chemical data
S 
Mol. mass 315.474 g/mol
Pharmacokinetic data
Bioavailability 37% (transdermal)
Protein binding 92%
CYP-mediated)
Half life 5 to 7 hours
Excretion Renal (71%) and fecal (23%)
Therapeutic considerations
Licence data

EU 

Pregnancy cat.

?

Legal status

POM(UK)

Routes Transdermal patch

Rotigotine is a non-ergot (or non-ergotamine) transdermal patches, so as to ensure a slow and constant dosage in a 24-hour period. The transdermal patch form of the drug has been given the trade name Neupro.

The drug has been approved by the Food and Drug Administration (FDA) as the first transdermal treatment of Parkinson's disease in the United States. In their press release the FDA mentioned the following side effects (among others): "skin reactions at the patch site, dizziness, nausea, vomiting, drowsiness and insomnia... are typical of this drug class."

As of 2006, the phase III clinical trial results showed that the drug was able to significantly reduce off time and increase on time without troublesome dyskinesia.

See also


v • d • e
Anti-parkinson drugs: Budipine
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rotigotine". A list of authors is available in Wikipedia.